Search

Displaying results 931 - 940 of 5383 in total
  1. Drug

    Fluvoxamine

    go.drugbank.com/drugs/DB00176
    ApprovedInvestigational

    Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database comprised of approximately 35,000 patients. … It was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine.

  2. Drug

    Dicloxacillin

    go.drugbank.com/drugs/DB00485
    ApprovedInvestigationalVet approved

    One of the penicillins which is resistant to penicillinase.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  3. Drug

    Metocurine

    go.drugbank.com/drugs/DB01336
    Approved

    Dimethyltubocurarinium (INN) or metocurine (USAN), also known as dimethyltubocurarine, is a non-depolarizing muscle relaxant.

  4. Drug

    N-Cyclohexyl-N'-phenyl-1,4-phenylenediamine

    go.drugbank.com/drugs/DB14196
    Approved

    N-Cyclohexyl-N'-phenyl-1,4-phenylenediamine is a component of black rubber. It is also a dermatological sensitizer and allergen. Sensitivity to N-Cyclohexyl-N'-phenyl-1,4-phenylenediamine may be identified with a clinical patch test.

    Mixtures: Test Thin-Layer Rapid Use Patch Test
  5. Drug

    Dibenzepin

    go.drugbank.com/drugs/DB13225
    Approved

    Dibenzepin is approved for use in Europe.

  6. Drug

    Tezacaftor

    go.drugbank.com/drugs/DB11712
    ApprovedInvestigational

    [L1595] It was developed by Vertex Pharmaceuticals and FDA approved in combination with [ivacaftor] to manage cystic fibrosis.[L6814] This drug was approved by the FDA on February 12, 2018. … [L4894] Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, an ion

  7. Drug

    Dosulepin

    go.drugbank.com/drugs/DB09167
    ApprovedInvestigational

    The use of dosulepsin is only recommended in patients who are intolerant or unresponsive to alternative antidepressant therapies. … Dosulepin (INN, BAN) formerly known as dothiepin (USAN), is a tricyclic antidepressant with anxiolytic properties that is used in several European and South Asian countries, as well as Australia, South

  8. Drug

    Valoctocogene roxaparvovec

    go.drugbank.com/drugs/DB15561
    ApprovedInvestigationalWithdrawn

    [L43282,A252807] Valoctocogene roxaparvovec was approved by EMA in September 2022 and is indicated for the treatment of severe hemophilia A. It is not approved for use in the United States. … [L43292] Hemophilia A treatments such as prophylactic regimens of exogenous factor VIII or [emicizumab] improve the clinical outcomes of patients but do not eliminate breakthrough bleeding.

  9. Drug

    Fidanacogene elaparvovec

    go.drugbank.com/drugs/DB16783
    ApprovedInvestigational

    [L49469,L46691] Fidanacogene elaparvovec was also approved by the FDA on April 26, 2024.[L50577] … [L46691] Hemophilia B is a rare X-linked genetic disorder characterized by abnormal coagulation due to dysfunctional coagulation factor IX with a male incidence estimated to be 1 in 30,000 male births

  10. Drug

    Fenofibric acid

    go.drugbank.com/drugs/DB13873
    ApprovedInvestigational

    Fenofibric acid is a lipid-lowering agent that is used in severe hypertriglyceridemia, primary hyperlipidemia, and mixed dyslipidemia. It works to decrease elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides, a...